EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 41 / Numéro 2 (Février 2025) Med Sci (Paris), 41 2 (2025) 154-159 Références
Open Access
Numéro
Med Sci (Paris)
Volume 41, Numéro 2, Février 2025
Page(s) 154 - 159
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2025011
Publié en ligne 3 mars 2025
  1. Abate-Shen C. Molecular genetics of prostate cancer. Genes Dev 2000 ; 14 : 2410–34. [CrossRef] [PubMed] [Google Scholar]
  2. Sakr WA, Haas GP, Cassin BF, et al. The Frequency of Carcinoma and Intraepithelial Neoplasia of the Prostate in Young Male Patients. J. Urol 1993 ; 150 : 379–85. [CrossRef] [PubMed] [Google Scholar]
  3. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005 ; 436 : 725–30. [CrossRef] [PubMed] [Google Scholar]
  4. Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 2016 ; 40 : 244–52. [CrossRef] [PubMed] [Google Scholar]
  5. Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. Nat Rev Dis Primers 2021 ; 7 : 9. [CrossRef] [PubMed] [Google Scholar]
  6. Galsky MD, Vogelzang NJ. Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol 2010 ; 21 : 2135–44. [CrossRef] [PubMed] [Google Scholar]
  7. Siddiqui BA, Subudhi SK, Sharma P. Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer. Cell Rep Med 2022 ; 3 : 100613. [CrossRef] [PubMed] [Google Scholar]
  8. Grelet É, Parisotto M, Metzger D. Comment limiter la progression des tumeurs prostatiques déficientes en PTEN ? Med Sci (Paris) 2018 ; 34 : 904–6. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  9. Dariane C, Baures M, Anract J, et al. Progéniteurs luminaux prostatiques: de la régénération tissulaire à la résistance thérapeutique. Med Sci (Paris) 2023 ; 39 : 429–36. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  10. Sackmann Sala L, Boutillon F, Menara G, et al. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours. J. Pathol 2017 ; 243 : 51–64. [CrossRef] [PubMed] [Google Scholar]
  11. Abu el Maaty MA, Terzic J, Keime C, et al. Hypoxia-mediated stabilization of HIF1A in prostatic intraepithelial neoplasia promotes cell plasticity and malignant progression. Sci Adv 2022 ; 8 : eabo2295. [CrossRef] [PubMed] [Google Scholar]
  12. Tuong ZK, Loudon KW, Berry B, et al. Resolving the immune landscape of human prostate at a single-cell level in health and cancer. Cell Rep 2021 ; 37 : 110132. [CrossRef] [PubMed] [Google Scholar]
  13. Linxweiler J, Hajili T, Körbel C, et al. Cancer-associated fibroblasts stimulate primary tumor growth and metastatic spread in an orthotopic prostate cancer xenograft model. Sci Rep 2020 ; 10 : 12575. [CrossRef] [PubMed] [Google Scholar]
  14. Bravi CA, Rosiello G, Fallara G, et al. Predictive value of preoperative neutrophil-to-lymphocyte ratio in localized prostate cancer: results from a surgical series at a high-volume institution. Minerva Urol Nephrol 2021 ; 73. [Google Scholar]
  15. Bancaro N, Calì B, Troiani M, et al. Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer. Cancer Cell 2023 ; 41 : 602–19.e11. [CrossRef] [PubMed] [Google Scholar]
  16. Calcinotto A, Spataro C, Zagato E, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature 2018 ; 559 : 363–9. [CrossRef] [PubMed] [Google Scholar]
  17. Guo C, Sharp A, Gurel B, et al. Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance. Nature 2023 ; 623 : 1053–61. [CrossRef] [PubMed] [Google Scholar]
  18. Lu X, Horner JW, Paul E, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 2017 ; 543 : 728–32. [CrossRef] [PubMed] [Google Scholar]
  19. Murphy AB, Nyame Y, Martin IK, et al. Vitamin D Deficiency Predicts Prostate Biopsy Outcomes. Clin Cancer Res 2014 ; 20 : 2289–99. [CrossRef] [PubMed] [Google Scholar]
  20. Manson JE, Cook NR, Lee IM, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med 2019 ; 380 : 33–44. [CrossRef] [PubMed] [Google Scholar]
  21. Feldman D, Krishnan AV, Swami S, et al. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 2014 ; 14 : 342–57. [CrossRef] [PubMed] [Google Scholar]
  22. Pike JW, Meyer MB, Lee S-M, et al. The vitamin D receptor: contemporary genomic approaches reveal new basic and translational insights. J Clin Invest 2017 ; 127 : 1146–54. [CrossRef] [PubMed] [Google Scholar]
  23. Belorusova AY, Rochel N. Structural Studies of Vitamin D Nuclear Receptor Ligand-Binding Properties. Vitam Horm 2016 : 83–116. [PubMed] [Google Scholar]
  24. Abu el Maaty MA, Grelet E, Keime C, et al. Single-cell analyses unravel cell type-specific responses to a vitamin D analog in prostatic precancerous lesions. Sci Adv 2021 ; 7 : eabg5982. [CrossRef] [PubMed] [Google Scholar]
  25. Belorusova AY, Rochel N. Structural Studies of Vitamin D Nuclear Receptor Ligand-Binding Properties. Vitam Horm 2016 : 83–116. [CrossRef] [PubMed] [Google Scholar]
  26. Banach-Petrosky W, Ouyang X, Gao H, et al. Vitamin D Inhibits the Formation of Prostatic Intraepithelial Neoplasia in Nkx3.1; Pten Mutant Mice. Clin Cancer Res 2006 ; 12 : 5895–901. [CrossRef] [PubMed] [Google Scholar]
  27. Shahvazi S, Soltani S, Ahmadi S, et al. The Effect of Vitamin D Supplementation on Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials. Horm Metab Res 2019 ; 51 : 11–21. [CrossRef] [PubMed] [Google Scholar]
  28. Beer T. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Sem Oncol 2001 ; 28 : 49–55. [CrossRef] [Google Scholar]
  29. Beer TM, Myrthue A. Calcitriol in the treatment of prostate cancer. Anticancer Res 2006 ; 26 : 2647–51. [PubMed] [Google Scholar]
  30. Abu el Maaty M, Wölfl S. Effects of 1,25(OH)2D3 on Cancer Cells and Potential Applications in Combination with Established and Putative Anti-Cancer Agents. Nutrients 2017 ; 9 : 87. [CrossRef] [PubMed] [Google Scholar]
  31. Beer TM. ASCENT: The androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU Int 2005 ; 96 : 508–13. [CrossRef] [PubMed] [Google Scholar]
  32. Medioni J, Deplanque G, Ferrero J, et al. Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for castration-resistant prostate cancer (CRPC) patients (pts). JCO 2011 ; 29 : 142. [CrossRef] [PubMed] [Google Scholar]
  33. Attia YM, El-Kersh DM, Ammar RA, et al. Inhibition of aldehyde dehydrogenase-1 and p-glycoprotein-mediated multidrug resistance by curcumin and vitamin D3 increases sensitivity to paclitaxel in breast cancer. Chem Biol Interact 2020 ; 315 : 108865. [CrossRef] [PubMed] [Google Scholar]
  34. Huang Z, Zhang Y, Li H, et al. Vitamin D promotes the cisplatin sensitivity of oral squamous cell carcinoma by inhibiting LCN2-modulated NF-κB pathway activation through RPS3. Cell Death Dis 2019 ; 10 : 936. [CrossRef] [PubMed] [Google Scholar]
  35. Len-Tayon K, Beraud C, Fauveau C, et al. A vitamin D-based strategy overcomes chemoresistance in prostate cancer. Br J Pharmacol 2024 ; bph.16492. [Google Scholar]
  36. Chauchereau A, Al Nakouzi N, Gaudin C, et al. Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer. Exp Cell Res 2011 ; 317 : 262–75. [CrossRef] [PubMed] [Google Scholar]
  37. Al Nakouzi N, Cotteret S, Commo F, et al. Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer. Oncotarget 2014 ; 5 : 667–78. [CrossRef] [PubMed] [Google Scholar]
  38. Galus Ł, Michalak M, Lorenz M, et al. Vitamin D supplementation increases objective response rate and prolongs progression-free time in patients with advanced melanoma undergoing anti-PD-1 therapy. Cancer 2023 ; 129 : 2047–55. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.